<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Formoterol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00983</strong>&#160; (APRD00641)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Formoterol is a long-acting (12 hours) beta2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (<span class="caps">COPD</span>). Inhaled formoterol works like other beta2-agonists, causing bronchodilatation through relaxation of the smooth muscle in the airway so as to treat the exacerbation of asthma.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00983/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00983/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00983.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00983.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00983.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00983.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00983.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00983">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Formoterolum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Formoterol fumarate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001072/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001072/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001072">DBSALT001072</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Foradil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Foradile</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oxeze Turbuhaler</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oxis Turbuhaler</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Perforomist</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Dulera</td><td>Mometasone + Formoterol</td></tr><tr><td>Symbicort 100 Turbuhaler</td><td>Budesonide + Formoterol Fumarate Dihydrate</td></tr><tr><td>Symbicort 200 Turbuhaler</td><td>Budesonide + Formoterol Fumarate Dihydrate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/sympathomimetics">Sympathomimetics</a></li>
<li><a href="/mesh/adrenergic-beta-2-receptor-agonists">Adrenergic beta-2 Receptor Agonists</a></li>
<li><a href="/mesh/bronchodilator-agents">Bronchodilator Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>73573-87-2</td></tr><tr><th>Weight</th><td>Average: 344.4049<br>Monoisotopic: 344.173607266</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>BPZSYCZIITTYBL-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Anisoles; Aminophenols; Alkyl Aryl Ethers; Secondary Alcohols; Secondary Carboxylic Acid Amides; 1,2-Aminoalcohols; Carboxylic Acids; Enols; Polyamines; Dialkylamines</td></tr><tr><th>Substituents</th><td>anisole; phenol ether; aminophenol; alkyl aryl ether; phenol derivative; 1,2-aminoalcohol; secondary carboxylic acid amide; secondary alcohol; polyamine; carboxylic acid derivative; ether; enol; carboxylic acid; secondary aliphatic amine; secondary amine; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator. Not indicated for asthma that can be successfully managed with occasional use of an inhaled, short-acting beta2-adrenergic agonist. Also used for the prevention of exercise-induced bronchospasm, as well as long-term treatment of bronchospasm associated with COPD.</td></tr><tr><th>Pharmacodynamics</th><td>Formoterol is a long-acting selective beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1- receptors. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10%-50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2- agonists may have cardiac effects.</td></tr><tr><th>Mechanism of action</th><td>The pharmacologic effects of beta2-adrenoceptor agonist drugs, including formoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibits the release of pro-inflammatory mast-cell mediators such as histamine and leukotrienes. Formoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed into plasma following administration by oral inhalation. It is likely that the majority of the inhaled formoterol delivered is swallowed and then absorbed from the gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>The binding of formoterol to human plasma proteins in vitro was 61%-64% at concentrations from 0.1 to 100 ng/mL. Binding to human serum albumin in vitro was 31%-38% over a range of 5 to 500 ng/mL. The concentrations of formoterol used to assess the plasma protein binding were higher than those achieved in plasma following inhalation of a single 120 &#181;g dose.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized primarily by direct glucuronidation at either the phenolic or aliphatic hydroxyl group and O-demethylation followed by glucuronide conjugation at either phenolic hydroxyl groups. Minor pathways involve sulfate conjugation of formoterol and deformylation followed by sulfate conjugation. The most prominent pathway involves direct conjugation at the phenolic hydroxyl group. The second major pathway involves O-demethylation followed by conjugation at the phenolic 2'-hydroxyl group. Four cytochrome P450 isozymes (CYP2D6, CYP2C19, CYP2C9 and CYP2A6) are involved in the O-demethylation of formoterol.</p></td></tr><tr><th>Route of elimination</th><td>Following inhalation of a 12 mcg or 24 mcg dose by 16 patients with asthma, about 10% and 15%-18% of the total dose was excreted in the urine as unchanged formoterol and direct conjugates of formoterol, respectively.</td></tr><tr><th>Half life</th><td>10 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Renal cl=150 mL/min [Healty subjects receiving oral administration of 80 mcg]</li>
</ul></td></tr><tr><th>Toxicity</th><td>An overdosage is likely to lead to effects that are typical of &#223;2-adrenergic stimulants: nausea, vomiting, headache, tremor, somnolence, palpitations, tachycardia, ventricular arrhythmias, metabolic acidosis, hypokalemia, hyperglycemia.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8991</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8026</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6916</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.747</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8773</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8561</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8818</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.714</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7086</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5556</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6609</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8757</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8442</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7517
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8704
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.992
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4047 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9611
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6602
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li>
<li>Dey pharma lp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.dey.com">Dey Pharma LP</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.schering.de">Schering Corp.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Aerosol, metered</td><td>Respiratory (inhalation)</td><td></td></tr><tr><td>Capsule</td><td>Respiratory (inhalation)</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like formoterol. Therapy should be monitored.</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. </td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Antagonism</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>